Biogen (BIIB) Shares May Not Benefit from the NCD Catalyst Next Week, Jefferies Thinks "It's Tricky"
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $325.00 price target on Biogen (NASDAQ: BIIB) ahead of NCD next ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
